The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Nov 2009 11:21

RNS Number : 2692C
CareCapital Group plc
10 November 2009
 

CareCapital Group plc

TR-1(i)NOTIFICATION OF MAJOR INTERESTS IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

CareCapital Group plc

2. Reason for the notification:

Disposal

3. Full name of person(s) subject to the notification obligation:

Credo Capital plc ("Credo")

4. Full name of shareholder(s):

Credo Group Holdings Limited and its subsidiary, Credo Capital plc

 

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

6 November 2009

6. Date on which issuer notified:

6 November 2009

7. Threshold(s) that is/are crossed or reached:

 9%

8. Notified details:

……………..

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the Triggering transaction (vi)

Number of shares

Number of voting Rights (viii)

GB00B16JQ761

6,995,884

6,995,884

Resulting situation after the triggering transaction (vii)

Class/type of shares if possible using the ISIN CODE

Number of shares 

Number of voting rights (ix)

% of voting rights

Direct

Direct (x)

Indirect (xi)

Direct

Indirect

6,859,561

1,666,462

5,193,099

2.17%

6.76%

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument

Expiration Date (xiii)

Exercise/Conversion Period/ Date (xiv)

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

Total (A+B)

Number of voting rights

% of voting rights

6,859,561

8.93%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

……………..

Proxy Voting:

10. Name of the proxy holder:

……………..

11. Number of voting rights proxy holder will cease to hold:

……………..

12. Date on which proxy holder will cease to hold voting rights:

……………..

13. Additional information:

……………..

14. Contact name:

Ivan Averbuch

15. Contact telephone number:

020 7968 8425

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBMBBTMMBBBLL
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.